Novel Drug Design for Treatment of COVID-19: A Systematic Review of Preclinical Studies

Abstract

Background. Since the beginning of the novel coronavirus (SARS-CoV-2) disease outbreak, there has been an increasing interest in discovering potential therapeutic agents for this disease. In this regard, we conducted a systematic review through an overview of drug development (in silico, in vitro, and in vivo) for treating COVID-19. Methods. A systematic search was carried out in major databases including PubMed, Web of Science, Scopus, EMBASE, and Google Scholar from December 2019 to March 2021. A combination of the following terms was used: coronavirus, COVID-19, SARS-CoV-2, drug design, drug development, In silico, In vitro, and In vivo. A narrative synthesis was performed as a qualitative method for the data synthesis of each outcome measure. Results. A total of 2168 articles were identified through searching databases. Finally, 315 studies (266 in silico, 34 in vitro, and 15 in vivo) were included. In studies with in silico approach, 98 article study repurposed drug and 91 studies evaluated herbal medicine on COVID-19. Among 260 drugs repurposed by the computational method, the best results were observed with saquinavir (n = 9), ritonavir (n = 8), and lopinavir (n = 6). Main protease (n = 154) following spike glycoprotein (n = 62) and other nonstructural protein of virus (n = 45) was among the most studied targets. Doxycycline, chlorpromazine, azithromycin, heparin, bepridil, and glycyrrhizic acid showed both in silico and in vitro inhibitory effects against SARS-CoV-2. Conclusion. The preclinical studies of novel drug design for COVID-19 focused on main protease and spike glycoprotein as targets for antiviral development. From evaluated structures, saquinavir, ritonavir, eucalyptus, Tinospora cordifolia, aloe, green tea, curcumin, pyrazole, and triazole derivatives in in silico studies and doxycycline, chlorpromazine, and heparin from in vitro and human monoclonal antibodies from in vivo studies showed promised results regarding efficacy. It seems that due to the nature of COVID-19 disease, finding some drugs with multitarget antiviral actions and anti-inflammatory potential is valuable and some herbal medicines have this potential.

COVID-19-Omics Report: From Individual Omics Approaches to Precision Medicine

“…Omics data have become an essential part of diagnostic medicine and have served as the basis for discoveries in precision and preventive medicine. Medical institutions initiated clinical trials of repurposed drugs, prompting pharmaceutical companies to begin development of novel therapeutics and vaccines [159][160][161].…”

Paving New Roads Using Allium sativum as a Repurposed Drug and Analyzing its Antiviral Action Using Artificial Intelligence Technology

“…New antiviral medications are desperately needed, as remdesivir's therapeutic results remain debatable. Here, we highlight the creation of novel SARS-CoV-2 infection therapies that have been carried out in fundamental research, given the urgency of the SARS-CoV-2 outbreak (20,(59)(60)(61).…”

Repositioned Natural Compounds and Nanoformulations: A Promising Combination to Counteract Cell Damage and Inflammation in Respiratory Viral Infections

“…For this reason, also considering the global health emergency of the last few years, numerous studies are aimed at developing new therapies for other respiratory viruses. In particular, several pre-clinical and clinical studies have been approved, and are still ongoing, to develop drugs against new viral targets, to increase potency and reduce resistance, also mitigating the strong responses of the host immune system [ 58 , 59 , 60 , 61 ]. Nevertheless, the processes of new drug discovery are very difficult.…”